AngioDynamics マネジメント
マネジメント 基準チェック /24
AngioDynamicsの CEO はJim Clemmerで、 Apr2016年に任命され、 の在任期間は 10.42年です。 の年間総報酬は$ 5.49Mで、 14.6%給与と85.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.52%を直接所有しており、その価値は$ 9.88M 。経営陣と取締役会の平均在任期間はそれぞれ7年と10.1年です。
主要情報
Jim Clemmer
最高経営責任者
US$5.5m
報酬総額
| CEO給与比率 | 14.62% |
| CEO在任期間 | 10.4yrs |
| CEOの所有権 | 1.5% |
| 経営陣の平均在職期間 | 7yrs |
| 取締役会の平均在任期間 | 10.1yrs |
経営陣の近況
Recent updates
Seeking Alpha • Jul 16
AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)
Summary AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum. But I downgrade to a hold as I see limited upside after the recent rally, premium valuation, and execution risk. Read the full article on Seeking Alpha分析記事 • Dec 05
The Market Doesn't Like What It Sees From AngioDynamics, Inc.'s (NASDAQ:ANGO) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 1.9x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...分析記事 • Oct 03
We Think AngioDynamics (NASDAQ:ANGO) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Aug 26
Revenues Working Against AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.3x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...
新しいナラティブ • May 30
FDA Approval And International Expansion Will Redefine Healthcare Delivery
Growth in proprietary therapies and expanding adoption of key platforms are driving improved margins, higher recurring revenues, and long-term earnings visibility.分析記事 • Jan 30
AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, AngioDynamics, Inc. ( NASDAQ:ANGO ) shares have been powering on, with a gain of 38% in...Seeking Alpha • Jan 16
AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares
Summary AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential. Shares have surged over 60%, yet further upside toward $20 remains if management can capitalize on Med Tech opportunities. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
AngioDynamics: A Surgical Approach To Market Growth
Summary AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue. Despite some challenges, AngioDynamics' strategic focus on high-growth markets and a healthy balance sheet make ANGO stock a solid “Buy” for long-term growth. Read the full article on Seeking Alpha分析記事 • Dec 10
There Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding
You may think that with a price-to-sales (or "P/S") ratio of 1.2x AngioDynamics, Inc. ( NASDAQ:ANGO ) is definitely a...分析記事 • Jul 19
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Shareholders of AngioDynamics, Inc. ( NASDAQ:ANGO ) will be pleased this week, given that the stock price is up 13% to...分析記事 • Jul 18
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified
The AngioDynamics, Inc. ( NASDAQ:ANGO ) share price has done very well over the last month, posting an excellent gain...Seeking Alpha • May 14
AngioDynamics: A Story To Monitor
Summary AngioDynamics, Inc. is struggling for profitability and its stock hit an all-time low of $5.26 on March 25th, 2024. However, the company is undergoing a restructuring, eliminating its manufacturing capabilities and focusing on its profitable medical technology business. Despite the challenges, the company has no debt, an increasingly higher margin portfolio, and insider buying, making its valuation potentially compelling. An analysis around AngioDynamics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Summary AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful. Progress toward double-digit adjusted EBITDA margins in four or five years can support a fair value of $10 today, but this is a highly speculative call. Read the full article on Seeking Alpha分析記事 • Apr 06
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
AngioDynamics, Inc. ( NASDAQ:ANGO ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Jan 14
AngioDynamics: Restructuring Initiative May Not Go Far Enough
Summary AngioDynamics' latest quarter earnings missed expectations. The company is facing weaker-than-anticipated sales following the rollout of new products forcing management to revise lower full-year guidance. We expect shares to remain volatile until there is evidence of stronger growth and a path to profitability. Read the full article on Seeking Alpha分析記事 • Oct 12
AngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Despite announcing strong earnings, AngioDynamics, Inc.'s ( NASDAQ:ANGO ) stock was sluggish. Our analysis uncovered...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| May 31 2026 | n/a | n/a | -US$37m |
| Feb 28 2026 | n/a | n/a | -US$31m |
| Nov 30 2025 | n/a | n/a | -US$28m |
| Aug 31 2025 | n/a | n/a | -US$32m |
| May 31 2025 | US$5m | US$803k | -US$34m |
| Feb 28 2025 | n/a | n/a | -US$41m |
| Nov 30 2024 | n/a | n/a | -US$225m |
| Aug 31 2024 | n/a | n/a | -US$243m |
| May 31 2024 | US$5m | US$783k | -US$184m |
| Feb 29 2024 | n/a | n/a | -US$192m |
| Nov 30 2023 | n/a | n/a | -US$14m |
| Aug 31 2023 | n/a | n/a | US$6m |
| May 31 2023 | US$4m | US$756k | -US$52m |
| Feb 28 2023 | n/a | n/a | -US$37m |
| Nov 30 2022 | n/a | n/a | -US$33m |
| Aug 31 2022 | n/a | n/a | -US$33m |
| May 31 2022 | US$6m | US$736k | -US$27m |
| Feb 28 2022 | n/a | n/a | -US$40m |
| Nov 30 2021 | n/a | n/a | -US$38m |
| Aug 31 2021 | n/a | n/a | -US$34m |
| May 31 2021 | US$4m | US$720k | -US$32m |
| Feb 28 2021 | n/a | n/a | -US$169m |
| Nov 30 2020 | n/a | n/a | -US$171m |
| Aug 31 2020 | n/a | n/a | -US$170m |
| May 31 2020 | US$3m | US$716k | -US$167m |
報酬と市場: Jimの 総報酬 ($USD 5.49M ) は、 US市場 ($USD 3.51M ) の同規模の企業の平均を上回っています。
報酬と収益: Jimの報酬は増加しましたが、会社は利益を上げていません。
CEO
Jim Clemmer (62 yo)
10.4yrs
在職期間
US$5,494,285
報酬
Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Interim President of...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 10.4yrs | US$5.49m | 1.52% $ 9.9m | |
| Executive VP & CFO | 6.9yrs | US$2.16m | 0.39% $ 2.5m | |
| Senior VP | 1.8yrs | US$1.46m | 0.069% $ 448.9k | |
| Senior Vice President of Regulatory Affairs | 9.4yrs | US$1.17m | 0.16% $ 1.0m | |
| Senior VP and GM of Cardiovascular & International | 5.3yrs | US$1.37m | 0.20% $ 1.3m | |
| Vice President of Communications | 6.6yrs | データなし | データなし | |
| Senior Vice President of Business Development & Strategy | 11.5yrs | データなし | データなし | |
| Senior Vice President of Human Resources | 7yrs | データなし | データなし | |
| Senior VP and GM of Oncology & Interventional Devices | 10.3yrs | US$1.01m | 0.15% $ 1.0m | |
| Senior Vice President of Information Technology | 15yrs | データなし | データなし | |
| Senior Vice President of Scientific & Clinical Affairs | 5.7yrs | データなし | データなし | |
| Global Vice President for Marketing-Oncology | no data | データなし | データなし |
7.0yrs
平均在職期間
57yo
平均年齢
経験豊富な経営陣: ANGOの経営陣は経験豊富で経験豊富です（平均在職期間は7年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 10.4yrs | US$5.49m | 1.52% $ 9.9m | |
| Independent Director | 9.8yrs | US$241.03k | 0.28% $ 1.8m | |
| Independent Director | 19.7yrs | US$246.03k | 0.38% $ 2.4m | |
| Independent Non-Executive Chairman | 22.5yrs | US$268.53k | 0.43% $ 2.8m | |
| Independent Director | 10.7yrs | US$238.53k | 0.28% $ 1.8m | |
| Independent Director | 7.2yrs | US$231.03k | 0.25% $ 1.6m | |
| Independent Director | 6.9yrs | US$228.53k | 0.23% $ 1.5m | |
| Independent Director | 3.2yrs | US$231.03k | 0.16% $ 1.1m |
10.1yrs
平均在職期間
64.5yo
平均年齢
経験豊富なボード: ANGOの 取締役会 は経験豊富で 経験豊富 です ( 10.1年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/16 08:22 |
| 終値 | 2026/09/16 00:00 |
| 収益 | 2026/05/31 |
| 年間収益 | 2026/05/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AngioDynamics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Matthew Taylor | Barclays |
| John Young | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |